Bcworldpharm KRX:200780KOSDAQ
비씨월드제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked6since Sep 11
In Q2 2026, Bcworldpharm reported revenue of ₩21.0bn, up 2.5% year on year, and operating profit of ₩147m. Bcworldpharm (비씨월드제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 20 with 2 articles. The most common catalyst was earnings (1).
Bcworldpharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩21.0bn | +2.5% | ₩147m margin 0.7% | −₩1000m |
| Q1 2026 | ₩19.8bn | +25.4% | ₩1.8bn margin 9.1% | ₩786m |
| Q4 2025 derived | ₩20.3bn | -5.8% | ₩719m margin 3.5% | −₩69m |
| Q3 2025 | ₩19.3bn | +9.9% | ₩148m margin 0.8% | −₩981m |
| Q2 2025 | ₩20.4bn | +5.0% | ₩1.8bn margin 8.9% | −₩217m |
| Q1 2025 | ₩15.8bn | -2.9% | −₩695m margin −4.4% | −₩1.9bn |
| Q4 2024 derived | ₩21.5bn | +9.9% | ₩2.0bn margin 9.1% | ₩907m |
| Q3 2024 | ₩17.5bn | -0.4% | ₩333m margin 1.9% | −₩849m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Bcworldpharm top stories 2 weeks, by number of outlets
- 1
- 2
- 3